Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 34Other hematologic neoplasm 16Plasma cell 14Gastrointestinal 10Thoracic 9Breast 7Other solid neoplasm 6Genitourinary 6Dermatologic 4Myeloid 3Gynecologic 3CNS 3Sarcoma 2Head & Neck 2Endocrine 1

Conditions

Sarcoma, Kaposi 1Sarcoma 1Osteosarcoma 1Multi-centric Castleman's Disease 1Melanoma 1Castleman Disease 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

Radiotherapy 220Doxorubicin 210Cyclophosphamide 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 80Irinotecan 79pembrolizumab 75Radiation 69Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Peripheral Blood Stem Cell Transplantation 57Surgical Procedures, Operative 56Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
tocilizumab × Sarcoma × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡